[HTML][HTML] Innate Immune Recognition of Mycobacterium tuberculosis

J Kleinnijenhuis, M Oosting, LAB Joosten… - Journal of Immunology …, 2011 - hindawi.com
J Kleinnijenhuis, M Oosting, LAB Joosten, MG Netea, R Van Crevel
Journal of Immunology Research, 2011hindawi.com
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a major health problem,
with 10 million new cases diagnosed each year. Innate immunity plays an important role in
the host defense against M. tuberculosis, and the first step in this process is recognition of
MTB by cells of the innate immune system. Several classes of pattern recognition receptors
(PPRs) are involved in the recognition of M. tuberculosis, including Toll-like receptors
(TLRs), C-type lectin receptors (CLRs), and Nod-like receptors (NLRs). Among the TLR …
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a major health problem, with 10 million new cases diagnosed each year. Innate immunity plays an important role in the host defense against M. tuberculosis, and the first step in this process is recognition of MTB by cells of the innate immune system. Several classes of pattern recognition receptors (PPRs) are involved in the recognition of M. tuberculosis, including Toll-like receptors (TLRs), C-type lectin receptors (CLRs), and Nod-like receptors (NLRs). Among the TLR family, TLR2, TLR4, and TLR9 and their adaptor molecule MyD88 play the most prominent roles in the initiation of the immune response against tuberculosis. In addition to TLRs, other PRRs such as NOD2, Dectin-1, Mannose receptor, and DC-SIGN are also involved in the recognition of M. tuberculosis. Human epidemiological studies revealed that genetic variation in genes encoding for PRRs and downstream signaling products influence disease susceptibility, severity, and outcome. More insight into PRRs and the recognition of mycobacteria, combined with immunogenetic studies in TB patients, does not only lead to a better understanding of the pathogenesis of tuberculosis but also may contribute to the design of novel immunotherapeutic strategies.
hindawi.com